DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1062 Clark AR. MAP kinase phosphatase 1: A novel mediator of biological
effects of glucocorticoids? J Endocrinol, 2003, 178:5–12.
Coreno A, Skowronski M, Kotaru C, McFadden ER Jr.
Comparative effects of long-acting beta2-agonists, leukotriene
receptor antagonists, and a 5-lipoxygenase inhibitor on
exercise-induced asthma. J Allergy Clin Immunol, 2000,
106:500–506.
Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline
enhances the anti-inflammatory effects of steroids during exacerbations
of chronic obstructive pulmonary disease. Thorax,
2009, 64:424–429.
Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone
deacetylase activity and steroid responses in COPD
macrophages. J Exp Med, 2004, 200:689–695.
Cox L, Platts-Mills TA, Finegold I, et al. American Academy of
Allergy, Asthma & Immunology/American College of Allergy,
Asthma and Immunology Joint Task Force Report on omalizumab-associated
anaphylaxis. J Allergy Clin Immunol, 2007,
120:1373–1377.
Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation,
function and role in human diseases. Biochim Biophys Acta,
2007, 1773:1358–1375.
Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline
on induced sputum inflammatory indices and neutrophil
chemotaxis in COPD. Am J Resp Crit Care Med, 2002, 165:
1371–1376.
Currow DC, Abernethy AP. Pharmacological management of
dyspnoea. Curr Opin Support Palliat Care, 2007, 1:96–101.
Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement
of aspirin-intolerant asthma by montelukast, a leukotriene
antagonist: a randomized, double-blind, placebo-controlled
trial. Am J Respir Crit Care Med, 2002, 165:9–14.
Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive
pulmonary disease (Bronchitis Randomized on NAC Cost-
Utility Study, BRONCUS): A randomised placebo-controlled
trial. Lancet, 2005, 365:1552–1560.
Delhase M, Li N, Karin M. Kinase regulation in inflammatory
response. Nature, 2000, 406:367–368.
Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol
and asthma control: The TRUST randomised trial.
Lancet, 2000, 355:1675–1679.
Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics
and pharmacodynamics of inhaled corticosteroids
to asthma. Eur Respir J, 2006, 28:1042–1050.
Dicpinigaitis PV. Currently available antitussives. Pulm Pharmacol
Ther, 2009a, 22:148–151.
Dicpinigaitis PV, Gayle YE, Solomon G, Gilbert RD. Inhibition
of cough-reflex sensitivity by benzonatate and guaifenesin in
acute viral cough. Respir Med, 2009b, 103:902–906.
Dini FL, Cogo R. Doxofylline: A new generation xanthine bronchodilator
devoid of major cardiovascular adverse effects.
Curr Med Res Opin, 2001, 16:258–268.
Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets
in chronic obstructive pulmonary disease. Trends
Pharmacol Sci, 2006, 27: 546–553.
Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor
antagonists as single agent asthma treatment: Systematic
review of current evidence. BMJ, 2003, 326:621–624.
Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists
versus anti-leukotrienes as add-on therapy to inhaled
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
corticosteroids for chronic asthma. Cochrane Database Syst
Rev, 2006, CD003137.
Duffy N, Walker P, Diamantea F, et al. Intravenous aminophylline
in patients admitted to hospital with non-acidotic exacerbations
of chronic obstructive pulmonary disease: A prospective randomised
controlled trial. Thorax, 2005, 60:713–717.
Emelyanov A, Fedoseev G, Barnes PJ. Reduced intracellular
magnesium concentrations in asthmatic subjects. Eur Respir J,
1999, 13:38–40.
Erin EM, Zacharasiewicz AS, Nicholson GC, et al. Rapid
anti-inflammatory effect of inhaled ciclesonide in asthma: A
randomised, placebo-controlled study. Chest, 2008, 134:
740–745.
Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of lowdose
inhaled budesonide plus theophylline and high-dose
inhaled budesonide for moderate asthma. N Engl J Med, 1997,
337:1412–1418.
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast
in moderate-to-severe chronic obstructive pulmonary disease
treated with long-acting bronchodilators: Two randomised clinical
trials. Lancet, 2009, 374:695–703.
Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate
safety and efficacy of mepolizumab in patients with moderate
persistent asthma. Am J Respir Crit Care Med, 2007,
176:1062–1071.
Fluge T, Forssmann WG, Kunkel G, et al. Bronchodilation using
combined urodilatin-albuterol administration in asthma: A randomized,
double-blind, placebo-controlled trial. Eur J Med
Res, 1999, 4:411–415.
Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of
asthma management: Toward understanding how long-acting
beta(2)-adrenoceptor agonists enhance the clinical efficacy of
inhaled corticosteroids. Br J Pharmacol, 2008, 153:1090–1104.
Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for
the treatment of pulmonary arterial hypertension. Eur Respir
J, 2008, 31:891–901.
Gompertz S, Stockley RA. A randomized, placebo-controlled
trial of a leukotriene synthesis inhibitor in patients with COPD.
Chest, 2002, 122:289–294.
Greenstone M, Lasserson TJ. Doxapram for ventilatory failure
due to exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, 2003, CD000223.
Gross JB, Blouin RT, Zandsberg S, et al. Effect of flumazenil on
ventilatory drive during sedation with midazolam and alfentanil.
Anesthesiology, 1996, 85:713–720.
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and
exacerbations of refractory eosinophilic asthma. N Engl J Med,
2009, 360:973–984.
Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective
inhibitor of inducible nitric oxide synthase inhibits exhaled
breath nitric oxide in healthy volunteers and asthmatics.
FASEB J, 2003, 17:1298–1300.
Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes
prolonged bronchoprotection and bronchodilatation in patients
with asthma. Chest, 2005, 128:1974–1979.
Haque RA, Usmani OS, Barnes, PJ. Chronic idiopathic cough:
a discrete clinical entity? Chest, 2005, 127:1710–1713.
Harrison TW, Wisniewski A, Honour J, Tattersfield AE.
Comparison of the systemic effects of fluticasone propionate
and budesonide given by dry powder inhaler in healthy and
asthmatic subjects. Thorax, 2001, 56:186–191.